Eosinophils Exert Antitumorigenic Effects in the Development of Esophageal Squamous Cell Carcinoma

Authors: Jacobse, Justin, Aziz, Zaryab, Sun, Lili, Chaparro, Jasmine, Pilat, Jennifer M., Kwag, Aaron, Buendia, Matthew, Wimbiscus, Mae, Nasu, Motomi, Saito, Tsuyoshi, Mine, Shinji, Orita, Hajime, Revetta, Frank, Short, Sarah P., Kay Washington, M., Hiremath, Girish, Gibson, Michael K., Coburn, Lori A., Koyama, Tatsuki, Goettel, Jeremy A., Williams, Christopher S., Choksi, Yash A.

Source: In Cellular and Molecular Gastroenterology and Hepatology 2023 16(6):961-983

Data Set for Reporting Carcinoma of the Stomach in Gastrectomy: Recommendations From the International Collaboration on Cancer Reporting

Authors: Shi, Chanjuan, Badgwell, Brian D., Grabsch, Heike I., Gibson, Michael K., Hong, Seung-Mo, Kumarasinghe, Priyanthi, Lam, Alfred K., Lauwers, Gregory, O Donovan, Maria, van der Post, Rachel S.

Source: Archives of pathology & laboratory medicine. 146(9):1072-1083

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN631355777&indx=1&recIds=ETOCRN631355777

Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.

Authors: Lander, Eric Michael, Aushev, Vasily N., Huffman, Brandon M., Hanna, Diana, Dutta, Punashi, Ferguson, Jenifer, Sharma, Shruti, Jurdi, Adham, Liu, Minetta C., Eng, Cathy, Klempner, Samuel J., Gibson, Michael K.

Source: JCO Precision Oncology; 12/6/2024, Vol. 8, p1-8, 8p

Subject Terms: CIRCULATING tumor DNA, PROGNOSIS, ESOPHAGOGASTRIC junction cancer, DISEASE relapse, NEOADJUVANT chemotherapy, PATHOLOGIC complete response, PROGRESSION-free survival

Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma.

Authors: Wheless, Margaret C., Comer, Margaret, Gibson, Michael K.

Source: Current Oncology Reports; Nov2024, Vol. 26 Issue 11, p1469-1488, 20p

Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5‐Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG‐ACRIN Cancer Research Group (E2205)

Authors: Gibson, Michael K., Catalano, Paul, Kleinberg, Lawrence R., Staley, Charles A., Montgomery, Elizabeth A., Jimeno, Antonio, Song, Wei (Frank), Mulcahy, Mary F., Leichman, Lawrence P., Benson, Al B.

Source: Oncologist. 25(1):e53-e59

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100099861896.0x000001&indx=1&recIds=ETOCvdc_100099861896.0x000001

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

Authors: Smith, Derek K., Cmelak, Anthony, Niermann, Ken, Ghiam, Michael, Lou, Diane, Gilbert, Jill, Gibson, Michael K., Hawkins, Deborah, Murphy, Barbara A.

Source: Head & neck. 42(12):3497-3505

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100112224412.0x000001&indx=1&recIds=ETOCvdc_100112224412.0x000001

Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives.

Authors: Kaur, Anahat¹ dr.anahatkaur@gmail.com, Gibson, Michael K.²

Source: touchREVIEWS in Oncology & Haematology. 2024, Vol. 20 Issue 2, p34-38. 5p.

Subject Terms: *IMMUNE checkpoint inhibitors, *GASTROINTESTINAL cancer, *SQUAMOUS cell carcinoma, *STATISTICAL significance, *NEOADJUVANT chemotherapy

Advances in Diagnosis and Multidisciplinary Management of Oropharyngeal Squamous Cell Carcinoma: State of the Art

Authors: Parvathaneni, Upendra, Lavertu, Pierre, Gibson, Michael K., Glastonbury, Christine M.

Source: Radiographics. 39(7):2055-2068

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN622136307&indx=1&recIds=ETOCRN622136307

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management

Authors: Kang, Kylie H., Grubb, William, Sawlani, Komal, Gibson, Michael K., Hoimes, Christopher J., Rogers, Lisa R., Lavertu, Pierre, Yao, Min

Source: American journal of otolaryngology. 39(5):642-645

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100065952788.0x000001&indx=1&recIds=ETOCvdc_100065952788.0x000001

A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes

Authors: Davison, Jon M., Landau, Michael S., Luketich, James D., McGrath, Kevin M., Foxwell, Tyler J., Landsittel, Douglas P., Gibson, Michael K., Nason, Katie S.

Source: In Clinical Gastroenterology and Hepatology March 2016 14(3):369-377

The distribution of esophageal cancer patients enrolled in care at the Uganda Cancer Institute by sub-regions, districts and ethnicity.

Authors: Obayo, Siraji, Mulumba, Yusuf, Thompson, Cheryl L., Gibson, Michael K., Cooney, Matthew M., Orem, Jackson

Source: African Health Sciences; Mar2024, Vol. 24 Issue 1, p206-213, 8p

An Ailment with Which I Will Contend: A Narrative Review of 5000 Years of Esophagogastric Cancers and Their Treatments, with Special Emphasis on Recent Advances in Immunotherapeutics.

Authors: Hilton, C. Beau, Lander, Steven, Gibson, Michael K.

Source: Cancers; Feb2024, Vol. 16 Issue 3, p618, 16p

Subject Terms: THERAPEUTIC use of antineoplastic agents, STOMACH tumors, IMMUNE checkpoint inhibitors, ESOPHAGEAL tumors, IMMUNOTHERAPY, PALLIATIVE treatment, CANCER patient medical care

The revised American Joint Committee on Cancer staging system (7th edition) improves prognostic stratification after minimally invasive esophagectomy for esophagogastric adenocarcinoma

Authors: Zahoor, Haris, Luketich, James D., Weksler, Benny, Winger, Daniel G., Christie, Neil A., Levy, Ryan M., Gibson, Michael K., Davison, Jon M., Nason, Katie S.

Source: In The American Journal of Surgery October 2015 210(4):610-617

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma

Authors: Zahoor, Haris, Luketich, James D., Levy, Ryan M., Awais, Omar, Winger, Daniel G., Gibson, Michael K., Nason, Katie S.

Source: In The Journal of Thoracic and Cardiovascular Surgery February 2015 149(2):538-547

MUC2 expression is an adverse prognostic factor in superficial gastroesophageal adenocarcinomas

Authors: Davison, Jon M., Ellis, Shane T., Foxwell, Tyler J., Luketich, James D., Gibson, Michael K., Kuan, Shih-Fan, Nason, Katie S.

Source: In Human Pathology March 2014 45(3):540-548

A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.

Authors: Patel, Shetal A.^1,2 (AUTHOR), Gibson, Michael K.³ (AUTHOR), Deal, Allison² (AUTHOR), Sheth, Siddharth^1,2 (AUTHOR), Heiling, Hillary² (AUTHOR), Johnson, Steven M.⁴ (AUTHOR), Douglas, Kathe² (AUTHOR), Flores, Melissa² (AUTHOR), Blumberg, Jeffrey⁵ (AUTHOR), Lumley, Catherine⁵ (AUTHOR), Yarbrough, Wendell G.⁵ (AUTHOR), Shen, Colette⁶ (AUTHOR), Chera, Bhishamjit S.⁷ (AUTHOR), Bauman, Jessica R.⁸ (AUTHOR), Hackman, Trevor⁵ (AUTHOR), Weiss, Jared¹ (AUTHOR) jared_weiss@med.unc.edu

Source: Cancer (0008543X). Nov2023, Vol. 129 Issue 21, p3381-3389. 9p.

Subject Terms: *SQUAMOUS cell carcinoma, *NEOADJUVANT chemotherapy, *IMMUNOTHERAPY, *ADVERSE health care events, *SURGICAL excision, *NECK

Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise.

Authors: Lander, Steve, Lander, Eric, Gibson, Michael K.

Source: Current Gastroenterology Reports; Nov2023, Vol. 25 Issue 11, p275-279, 5p

Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis

Authors: Li, Xuanyi, Sigworth, Elizabeth A., Wu, Adrianne H., Behrens, Jess, Etemad, Shervin A., Nagpal, Seema, Go, Ronald S., Wuichet, Kristin, Chen, Eddy J., Rubinstein, Samuel M., Venepalli, Neeta K., Tillman, Benjamin F., Cowan, Andrew J., Schoen, Martin W., Malty, Andrew, Greer, John P., Fernandes, Hermina D., Seifter, Ari, Chen, Qingxia, Chowdhery, Rozina A., Mohan, Sanjay R., Dewdney, Summer B., Osterman, Travis, Ambinder, Edward P., Buchbinder, Elizabeth I., Schwartz, Candice, Abraham, Ivy, Rioth, Matthew J., Singh, Naina, Sharma, Sanjai, Gibson, Michael K., Yang, Peter C., Warner, Jeremy L.

Source: Scientific reports. 10(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100175963304.0x000001&indx=1&recIds=ETOCvdc_100175963304.0x000001

Oesophageal carcinoma

Authors: Pennathur, Arjun, Gibson, Michael K, Jobe, Blair A, Luketich, James D

Source: In The Lancet 2-8 February 2013 381(9864):400-412

Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer.

Authors: Al Karmi, Joud¹ joudkarmi99@gmail.com, Gibson, Michael K.^2,3

Source: touchREVIEWS in Oncology & Haematology. 2023, Vol. 19 Issue 2, p16-21. 6p.

Subject Terms: *ANTIBODY-dependent cell cytotoxicity, *SYMPTOMS, *PROGNOSIS, *CYTOTOXINS, *CLAUDINS